CD4+ chimeric antigen receptor T cells in for the long journey
- PMID: 35307873
- DOI: 10.1111/imcb.12545
CD4+ chimeric antigen receptor T cells in for the long journey
Abstract
In a recently published article, Melenhorst et al. performed a longitudinal analysis on chimeric antigen receptor (CAR) T cells isolated from patients over 10 years after therapy, revealing expansion of a long-lived CD4+ CAR T-cell population with a cytotoxic phenotype.
Keywords: chimeric antigen receptor T cells; cytotolytic CD4+ T cells; persistence.
© 2022 Australian and New Zealand Society for Immunology, Inc.
Comment on
-
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2. Nature. 2022. PMID: 35110735 Free PMC article.
References
-
- Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
-
- Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
-
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
-
- Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018; 378: 449-459.
-
- Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24: 563-571.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
